drugset

drugset / Trial / NCT04512339

Dupilumab in Severe Chronic Hand Eczema

NCT04512339 ↗

Phase 2 Unknown 30 enrolled University Medical Center Groningen Genzyme, a Sanofi Company · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.

Timeline

Start: 2020-08-01
Primary completion: 2022-08
Completion: 2022-08

Publications

Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023 Sep 15;189(4):400-409. doi: 10.1093/bjd/ljad156.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dupilumab	Monoclonal antibody	300 mg	Subcutaneous

Indications